5 Trends for Life Science Companies to Watch in 2021

Submission to Australian House of Representatives inquiry into approval processes for new drugs

‘Roll with the punches and get to what’s real’: reflections on 2020

COVID-19 vaccination a 12-month success for science, governments and industry

A little less conversation, a little more action please: the global state of AMR

Non-communicable diseases and the global countdown to 2030

The next 20-year PBS agenda: government commitments to new medicines spending

PBS New Medicines Funding Guarantee: echoes of elections past ...

The new frontier: emerging regulatory issues in cell and gene therapies

This could get messy: Trump’s New ‘Most Favoured Nation’ Executive Order on Medicine Pricing

What future from a ‘no-deal’ Brexit for UK life sciences?

What would Dr Who say?: Time travel and the macroeconomic impact of COVID-19

President Trump’s new ‘Buy American’ executive order on essential medical products and implications

The economist, the activist and the epiphany: an argument about efficiency in health spending

Global trends in cardiovascular deaths: 30 years of country data

Spanish Flu vs COVID-19: medical technology and health system resilience

Covid-19 - So how are we doing? Lessons from USA, UK and France and how to move forward

Creeping Through the Backdoor: Disruption in Medicine and Health

When profit isn’t everything: 46,000 years of cultural history vs the iron ore spot price

Drones are taking off in healthcare